EHMT2 and Alzheimer disease: Thus, the pronounced reduction in CB2R gene expression across treated groups, particularly with G9a inhibition and dual treatments, further supports the hypothesis that targeting G9a modulates microglial activation states, as CB2R is typically upregulated in reactive glia associated with AD pathology [57].